CellSource Co (TSE:4880) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jan. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CellSource Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CellSource Co's cash to debt ratio for the quarter that ended in Jan. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, CellSource Co could pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for CellSource Co's Cash-to-Debt or its related term are showing as below:

TSE:4880' s Cash-to-Debt Range Over the Past 10 Years
Min: 47.97 Med: No Debt Max: No Debt
Current: 47.97

During the past 7 years, CellSource Co's highest Cash to Debt Ratio was No Debt. The lowest was 47.97. And the median was No Debt.

TSE:4880's Cash-to-Debt is ranked better than
71.66% of 1489 companies
in the Biotechnology industry
Industry Median: 6.91 vs TSE:4880: 47.97

CellSource Co Cash-to-Debt Historical Data

The historical data trend for CellSource Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CellSource Co Cash-to-Debt Chart

CellSource Co Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Cash-to-Debt

Get a 7-Day Free Trial

182.08

410.04

2,196.28

No Debt

49.02

CellSource Co Quarterly Data
	Oct18	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	49.02	No Debt

Competitive Comparison of CellSource Co's Cash-to-Debt

For the Biotechnology subindustry, CellSource Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CellSource Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CellSource Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where CellSource Co's Cash-to-Debt falls into.

CellSource Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

CellSource Co's Cash to Debt Ratio for the fiscal year that ended in Oct. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4781.022	/	(20.251	+	77.291)
	=	49.02

CellSource Co's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

CellSource Co had no debt ⁽¹⁾.

CellSource Co (TSE:4880) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

CellSource Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of CellSource Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CellSource Co (TSE:4880) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CellSource Co Ltd (TSE:4880) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002

Website

https://www.cellsource.co.jp

CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.

CellSource Co (TSE:4880) Headlines

No Headlines

CellSource Co (TSE:4880) Cash-to-Debt : No Debt (1) (As of Jan. 2024)